预约演示
更新于：2025-01-24
Dexibuprofen
右布洛芬
更新于：2025-01-24
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1998-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-JTQLQIEISA-N |
CAS号51146-56-6 |
关联
22
项与 右布洛芬 相关的临床试验ChiCTR2400093489
Evaluation of the safety and efficacy of dexibuprofen in improving fever symptoms in children aged 6 months to 3 years: a multicenter post marketing clinical study
CTR20242540
JC002餐后比较药代动力学临床试验
CTR20240968
JC002比较药代动力学临床试验
100 项与 右布洛芬 相关的临床结果
登录后查看更多信息
100 项与 右布洛芬 相关的转化医学
登录后查看更多信息
100 项与 右布洛芬 相关的专利（医药）
登录后查看更多信息
661
项与 右布洛芬 相关的文献（医药）2025-03-01COLLOIDS AND SURFACES B-BIOINTERFACES
Dexibuprofen loaded into nanoemulsion based gel for topical application – In vitro characterization and in vivo anti-inflammatory evaluation
Article
作者: Irfan, Muhammad ; Khalid, Ikrima ; Shah, Pervaiz Akhtar ; Asghar, Sajid ; Munir, Muhammad Rehan ; Asif, Muhammad ; Khan, Ikram Ullah ; Albekairi, Norah A ; Munir, Rabia ; Khalid, Syed Haroon ; Kamal, Yousaf ; Alshammari, Abdulrahman
Arthritic disease is one of the most common diseases in adults and a leading cause of joint degeneration. Dexibuprofen (DEX) is routinely used for the treatment of rheumatoid arthritis, acute postoperative pain, primary dysmenorrheal, and in lower back pain. However, it is poorly water soluble with compromised bioavailability, and hence has limited therapeutic activity. In order to overcome these issues, we studied the formulation and characterization of nanoemulsion based system i.e nanoemulgel of DEX. This study aimed to prepare topical nanoemulgel containing 2 % DEX and solubility-enhanced DEX via ternary inclusion complexation (DEX-SE-T) and to compare it with commercially available 5 % Ibuprofen gel as there is no topical formulation of DEX is available in the market currently. A pseudoternary phase diagram was constructed using the spontaneous water titration method. Blank and drug-loaded nanoemulgel were prepared using a high-speed homogenization method. All the formulations were evaluated in terms of particle size, pH, conductivity, viscosity, zeta potential, and ex vivo drug permeation. DEX loaded nanoemulgel yield enhanced in vitro skin permeation than the commercially available 5 % ibuprofen gel. The optimized nanoemulgel formulation (DEX-SE-T) was tested in in vivo anti-inflammatory models including cotton pellets-induced abdominal granuloma (chronic inflammation) and carrageenan-induced paw edema (acute inflammation). DEX-SE-T loaded nanoemulgel has improved in vivo anti-inflammatory activity as compared to ibuprofen gel. DEX-SE-T could be a promising option for effective topical treatment of inflammatory conditions.
2025-01-14ENVIRONMENTAL SCIENCE & TECHNOLOGY
Enantioselective Toxicity of Ibuprofen to Earthworms: Unraveling the Effect and Mechanism on Enhanced Toxicity of S-Ibuprofen Over R-Ibuprofen
Article
作者: Chen, Haonan ; Zhao, Qi ; Zhang, Xu-Xiang ; Zhao, Zeyu ; Jiang, Wenqi ; He, Xiwei ; Wu, Gang
With the global implementation of wastewater reuse, accurately assessing the soil ecological risk of chiral pollutants from wastewater necessitates a comprehensive understanding of their enantioselective toxicity to soil animals. Ibuprofen (IBU) is the most prevalent chiral pharmaceutical in municipal wastewater. However, its enantioselective toxicity toward soil animals and the underlying mechanism remain largely unknown. In this study, the toxicity of IBU enantiomers, S-IBU and R-IBU, to earthworms was evaluated at environmentally relevant concentrations (10 and 100 μg/L), simulating wastewater reuse for irrigation. The results demonstrated that IBU adversely affects the growth, reproduction, regeneration, defense systems, and metabolic processes of earthworms, with S-IBU exhibiting stronger toxic effects than R-IBU. The bioavailability assessment revealed that S-IBU was more readily absorbed by earthworms and converted to its enantiomer within earthworms than R-IBU. This is consistent with molecular docking results showing that S-IBU had stronger affinities for functional proteins associated with xenobiotic transport and transformation. The findings of this study highlight that S-IBU poses a higher risk than R-IBU to soil organisms under wastewater reuse scenarios and that the chirality of chemical pollutants in wastewater deserves more attention when implementing wastewater reuse. In addition, our study underscores that the differences in bioavailability and bioactivity may account for the enantioselective toxicity of chiral pollutants.
2025-01-08Journal of the American Chemical Society
Catalytic Asymmetric Oxidative Coupling between C(sp3)–H Bonds and Carboxylic Acids
Article
作者: Li, Fu ; Zhou, Qi-Lin ; Liu, Jing-Yuan ; Yang, Yin ; Dai, Ling ; Xiao, Li-Jun ; Jiang, Neng-Quan ; Xue, Li-Yuan ; Liu, Xian-Ming ; Xue, Xiao-Song ; Wang, Tongkun
The direct enantioselective functionalization of C(sp3)-H bonds in organic molecules could fundamentally transform the synthesis of chiral molecules. In particular, the enantioselective oxidation of these bonds would dramatically change the production methods of chiral alcohols and esters, which are prevalent in natural products, pharmaceuticals, and fine chemicals. Remarkable advances have been made in the enantioselective construction of carbon-carbon and carbon-nitrogen bonds through the C(sp3)-H bond functionalization. However, the direct enantioselective formation of carbon-oxygen bonds from C(sp3)-H bonds remains a considerable challenge. We herein report a highly enantioselective C(sp3)-H bond oxidative coupling with carboxylic acids. The method applies to allylic and propargylic C-H bonds and employs various carboxylic acids as oxygenating agents. The method successfully synthesized a range of chiral esters directly from readily available alkenes and alkynes, greatly simplifying the synthesis of chiral esters and related alcohols.
100 项与 右布洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 韩国 | 2007-12-31 | |
| 头痛 | 阿根廷 | - | 2007-04-16 |
| 背痛 | 阿根廷 | - | 2007-04-02 |
| 肌肉骨骼疼痛 | 阿根廷 | - | 2007-04-01 |
| 痛经 | 英国 | - | 2007-03-14 |
| 发热 | 中国 | 2001-01-01 | |
| 骨关节炎 | 中国 | - | 2001-01-01 |
| 类风湿关节炎 | 中国 | - | 2001-01-01 |
| 疼痛 | 瑞士 | - | 1998-05-21 |
| 风湿性疾病 | 瑞士 | - | 1998-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床2期 | 中国 | 2021-07-13 | |
| 镇痛 | 临床2期 | 中国 | 2021-07-13 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 急性疼痛 | 临床2期 | 美国 | 2018-01-12 | |
| 肌痛 | 临床2期 | 美国 | 2015-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 251 | (Active Arm) | 餘簾餘淵壓糧遞築鏇衊(窪壓獵夢鬱衊遞鹹觸構) = 觸觸廠構繭鬱範獵膚鹽 鹽鏇願積製顧願艱餘鏇 (夢鬱網夢選膚繭夢蓋窪, 艱齋獵鏇觸築膚願選構 ~ 鏇簾齋鹹鏇窪鑰衊繭簾) 更多 | - | 2022-01-25 | ||
Vehicle (Placebo Arm) | 餘簾餘淵壓糧遞築鏇衊(窪壓獵夢鬱衊遞鹹觸構) = 壓構壓鏇網膚膚餘衊鹽 鹽鏇願積製顧願艱餘鏇 (夢鬱網夢選膚繭夢蓋窪, 艱齋衊夢衊淵醖鹹遞夢 ~ 蓋觸範膚膚鏇壓窪願窪) 更多 | ||||||
临床3期 | 263 | 製糧願鏇鏇繭範蓋鑰膚(遞襯願鑰願餘窪願築淵) = 鑰鑰積夢築淵淵願鹽膚 願餘蓋醖淵艱簾壓蓋壓 (夢蓋鏇鹽壓鬱廠鑰鬱積 ) | - | 2018-06-23 | |||
製糧願鏇鏇繭範蓋鑰膚(遞襯願鑰願餘窪願築淵) = 構醖憲蓋顧願蓋鏇廠衊 願餘蓋醖淵艱簾壓蓋壓 (夢蓋鏇鹽壓鬱廠鑰鬱積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用